Relapsed Neuroblastoma

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma

NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma

A Multi-Arm, Platform Trial For Relapsed Neuroblastoma

GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma

PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma

Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma

Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma

MIBG for Refractory Neuroblastoma and Pheochromocytoma

67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma

Parental Decision-Making for Children With Relapsed Neuroblastoma

C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)

Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma

NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma

A Trial Using Molecular-Guided Therapy in Patients With Refractory or Recurrent Neuroblastoma

Standardized Protocol of Surgery and Radiation for Patients With Brain Metastases in Relapsed Neuroblastoma

Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2

DNA Vaccination Against Neuroblastoma